Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders
AssigneePoxel
InventorsSheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
Life of this patent
Estimating the term…
Abstract
The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.
Claims23
1-50. (canceled)
A method of treating nonalcoholic steatohepatitis, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the nonalcoholic steatohepatitis;
- wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1, A2, A3, and A4 are independently —C(R9)(R10)—;
- A5 is —C(R11)(R12)(R13);
- R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
- R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
- and
- Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
- and
- the second therapeutic agent comprises pentoxifylline, metformin, obeticholic acid, simtuzumab, aramchol, GFT-505 ((E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid), IMM-124E (bovine colostrum powder, harvested from cows immunized with lipopolysaccharide vaccine), cenicriviroc, metreleptin, sitagliptin, GR-MD-02 (compound developed by Galectin), SHP626 (compound developed by Shire), or a pharmaceutically acceptable salt thereof.
A method of treating a diabetes selected from the group consisting of Type I diabetes mellitus and Type II diabetes mellitus, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the diabetes;
- wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1, A2, A3, and A4 are independently —C(R9)(R10)—;
- A5 is —C(R11)(R12)(R13);
- R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
- R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
- and
- Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
- and
- the second therapeutic agent comprises metformin, a dipeptidyl peptidase IV inhibitor, a statin, an agonist of glucagon-like peptide-1, an agonist of glucagon-like peptide-2, an inhibitor of sodium/glucose cotransporter 2, insulin, an insulin analog, a GRP40 agonist, an alpha-glucosidase inhibitor, an incretin, an anti-hypertensive agent, pramlintide, benfluorex, leptin, glyburide, gliclazide, glimepiride, glipizide, tolbutamide, tolazamide, chlorpropamide, nateglinide, repaglinide, mitiglinide, or a pharmaceutically acceptable salt thereof.
A method selected from:
- (a) a method of treating nonalcoholic fatty liver disease, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the nonalcoholic fatty liver disease;
- wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1, A2, A3, and A4 are independently —C(R9)(R10)—;
- A5 is —C(R11)(R12)(R13);
- R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
- R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
- and
- Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
- and
- the second therapeutic agent comprises saroglitazar, vitamin D, cysteamine bitartrate, IDN-6556, losartan, sitagliptin, docosahexaenoic acid, eicosapentaenoic acid, pradigastat, berberine, an omega 3 fatty acid ester, resveratrol, Px-104, vitamin E, RO5093151, liraglutide, insulin glargine, lobeglitazone, oltipraz, S-adenosyl-L-methionine, amlexanox, rifampicin, pitavastatin, or a pharmaceutically acceptable salt thereof;
- (b) a method of treating a fibrotic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the fibrotic disorder;
- wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1, A2, A3, and A4 are independently —C(R9)(R10)—;
- A5 is —C(R11)(R12)(R13);
- R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
- R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
- and
- Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
- and
- the second therapeutic agent comprises entecavir, IDN-6556, DCB-BO1202, FG-3019, ND-L02-s0201, docosahexaenoic acid, Vitamin E, choline, cenicriviroc, GR-MD-02, raltegravir, rifaximin, S-adenosylmethionine, tenofovir disoproxil fumarate, emtricitabine, adefovir dipivoxil, pentoxifylline, simtuzumab, or a pharmaceutically acceptable salt thereof;
- (c) a method of treating liver cancer, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the liver cancer;
- wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1, A2, A3, and A4 are independently —C(R9)(R10)—;
- A5 is —C(R11)(R12)(R13);
- R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
- R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
- and
- Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
- and
- the second therapeutic agent comprises sorafenib, OMP-54F28, trametinib, TRC 105, tremelimumab, tivozanib, glass microspheres containing radioactive yttrium-90, refametinib, regorafenib, erlotinib, vorinostat, PD-033299, TKM-080301, tivantinib, ramucirumab, DCB-BO1202, LY2875358, galunisertib, erismodegib, cabozantinib, nivolumab, MSC2156119J, temsirolimus, OPB-111077, DCR-MYC, CC-223, donafenib, INC280, CC-122, oprozomib, CF102, SGI-110, artesunate, dalantercept, lenvatinib, colchicine, metformin, pentamidine, or a pharmaceutically acceptable salt thereof, and
- (d) a method of treating a disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, systemic lupus erythematosus, chronic kidney disease, asthma, chronic obstructive pulmonary disease, neuropathic pain, diabetic neuropathy, fibromyalgia, ulcerative colitis, and arthritis, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the disorder;
- wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1, A2, A3, and A4 are independently —C(R9)(R10)—;
- A5 is —C(R11)(R12)(R13);
- R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
- R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
- and
- Z is H or D, provided that the abundance of deuterium in Z is at least 30%.
Dependencies are inferred from the claim text.